UPDATE: NewLink Genetics Says Will Host Conference Call on Tues., May 10 at 8:30 a.m. EDT to Discuss Results from Phase 3 IMPRESS Trial of Algenpantucel-L, Did Not Achieve Primary Endpoint
Paul Quintaro